Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by Zacks Research

Omnicell (NASDAQ:OMCL) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

OMCL has been the topic of a number of other research reports. Wells Fargo & Company reduced their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp restated an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $57.86.

Omnicell Price Performance

OMCL stock opened at $38.03 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.65 and a quick ratio of 1.45. Omnicell has a one year low of $31.75 and a one year high of $55.00. The stock has a market cap of $1.73 billion, a PE ratio of 39.61, a P/E/G ratio of 0.98 and a beta of 0.88. The firm has a 50 day simple moving average of $34.85 and a two-hundred day simple moving average of $38.84.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, October 29th. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The firm had revenue of $307.85 million for the quarter, compared to analysts’ expectations of $304.44 million. During the same quarter last year, the company posted $0.51 EPS. The business’s quarterly revenue was down .9% on a year-over-year basis. On average, analysts predict that Omnicell will post 1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of OMCL. BlackRock Inc. bought a new stake in shares of Omnicell in the second quarter worth about $313,044,000. Dimensional Fund Advisors LP increased its holdings in Omnicell by 6.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 2.0% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock valued at $47,095,000 after purchasing an additional 27,497 shares during the period. Bank of America Corp DE raised its position in Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the last quarter. Finally, First Light Asset Management LLC bought a new position in Omnicell during the 1st quarter valued at approximately $16,351,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Key Stories Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks said solid upward earnings-estimate revisions could support further near-term gains, and added OMCL to its Rank #1 (Strong Buy) lists for November 5, including its momentum and value selections. Why Omnicell Might be Well Poised for a Surge New Strong Buy Stocks
• Positive Sentiment: Analyst price targets imply substantial potential upside, with one report citing a consensus target of $57.86 and another estimating 40.8%. The article cautions that price targets alone have limited predictive value; estimate revisions may be a more meaningful near-term signal. Omnicell Consensus Target Price Omnicell Potential Rally
• Neutral Sentiment: Omnicell was included in a roundup of robotics stocks with long-term growth potential, but the article offered no new company-specific catalyst. Top Robotics Stocks
• Negative Sentiment: The recent earnings backdrop is mixed: Omnicell beat quarterly EPS and revenue estimates, but revenue was down 0.9% year over year. That modest decline may temper optimism around the positive estimate-revision signals.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.